Overview

Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir

Status:
COMPLETED
Trial end date:
2025-02-03
Target enrollment:
Participant gender:
Summary
Enroll patients who are pre-treated with Entecavir at least 24 weeks and confirmed HBV antiviral (HBV DNA \<69 IU/mL) effects. Subjects are given one test drug or comparator once a day for 48 weeks according to the results of random assignments, and their HBV antiviral inhibitory effect and safety are evaluated at 24 and 48 weeks visits.
Phase:
PHASE4
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.